Chemomab Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2020
Selling, General & Admin	3.51	3.41	7.08	11.56	6.03	1.29	Upgrade
Research & Development	10.67	11.33	18.38	16.98	6.33	4.68	Upgrade
Operating Expenses	14.18	14.74	25.46	28.53	12.37	5.97	Upgrade
Operating Income	-14.18	-14.74	-25.46	-28.53	-12.37	-5.97	Upgrade
Interest Expense	-	-	-	-	-0.11	-	Upgrade
Interest & Investment Income	0.77	0.79	1.22	0.35	-	0.04	Upgrade
Currency Exchange Gain (Loss)	0.01	0.01	0.01	-	-	-0.02	Upgrade
Pretax Income	-13.4	-13.95	-24.22	-28.18	-12.48	-5.95	Upgrade
Income Tax Expense	-	-	-	-0.53	-	-	Upgrade
Net Income	-13.4	-13.95	-24.22	-27.65	-12.48	-5.95	Upgrade
Net Income to Common	-13.4	-13.95	-24.22	-27.65	-12.48	-5.95	Upgrade
Shares Outstanding (Basic)	20	18	12	11	10	7	Upgrade
Shares Outstanding (Diluted)	20	18	12	11	10	7	Upgrade
Shares Change (YoY)	60.31%	52.79%	3.26%	9.70%	51.71%	-	Upgrade
EPS (Basic)	-0.67	-0.78	-2.06	-2.43	-1.20	-0.87	Upgrade
EPS (Diluted)	-0.67	-0.78	-2.06	-2.43	-1.20	-0.87	Upgrade
Free Cash Flow	-	-15.39	-23.61	-20.44	-12.61	-5.28	Upgrade
Free Cash Flow Per Share	-	-0.86	-2.01	-1.80	-1.22	-0.77	Upgrade
EBITDA	-14.13	-14.69	-25.39	-28.48	-12.33	-5.95	Upgrade
D&A For EBITDA	0.05	0.05	0.07	0.06	0.03	0.02	Upgrade
EBIT	-14.18	-14.74	-25.46	-28.53	-12.37	-5.97	Upgrade

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q